Triplet Therapeutics
Deb Gouveia joined Triplet Therapeutics, Inc. as Vice President, Clinical Operations in September 2020. She has more than 25 years of experience in global pharmaceutical development and operations. Deb previously served as VP, Clinical Operations at Angion, where she played a critical role in establishing the clinical operations function and supporting both early and late-stage clinical programs. Prior to that, she held multiple senior leadership positions in clinical operations, clinical development, program management, and regulatory affairs across several companies including Stealth Biotherapeutics, Atreaon, MGI Pharma and Logical Therapeutics. Her experience spans across many therapeutic areas including Cardiorenal, Oncology, Infectious disease and Orphan/Rare disease. Deb holds a BS in Biology from the University of Massachusetts.
This person is not in any offices
Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.